Dyskinesia in Parkinson disease: Back for the future?

Neurology

Volumn 72, Issue 14, 2009, Pages 1202-1203

  Vingerhoets, Francois J G ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DIHYDROTETRABENAZINE; ENTACAPONE; LEVODOPA; METHYLPHENIDATE; ANTIPARKINSON AGENT; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TETRABENAZINE;

AGE; CONTROLLED RELEASE FORMULATION; DISEASE DURATION; DISEASE SEVERITY; DOPAMINE UPTAKE; DOWN REGULATION; DYSKINESIA; EDITORIAL; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; UPREGULATION; DRUG EFFECT; NOTE; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SYNAPSE;

ANTIPARKINSON AGENTS; DOPAMINE AGENTS; DYSKINESIAS; HUMANS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SYNAPSES; TETRABENAZINE;

EID: 65249135462     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000345658.54511.31     Document Type: Editorial

References (9)

1. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
2. Pahwa R, Factor SA, Lyons KE, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-995.
3. Cenci MA. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 2007; 30:236-243.
4. de la Fuente-Fernandez R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001;49:298- 303.
5. Nutt JG. Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa? Mov Disord 2007;22:1-9.
6. Troiano AR, de la Fuente-Fernandez R, Sossi V, et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 2009;72:1211-1216.
7. Vander Borght TM, Kilbourn MR, Koeppe RA, et al. In vivo imaging of the brain vesicular monoamine transporter. J Nucl Med 1995;36:2252-2260.
8. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000;47:493-503.
9. Sossi V, de la Fuente-Fernandez R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol 2007;62:468-474.